BioCentury
ARTICLE | Company News

Faulk Pharmaceuticals, Panther Biotechnology deal

April 27, 2015 7:00 AM UTC

Panther will acquire Faulk’s pharmaceutical assets, including TRF-DOX, for an undisclosed number of Panther shares. TRF-DOX is a ligand-drug conjugate of transferrin glycoproteins and doxorubicin fo...